TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the phase III COVACTA study of Actemra (tocilizumab) did not meet its primary endpoint of improved clinical status in hospitalized adult patients with severe COVID-19 associated pneumonia.

In addition, the key secondary endpoints, which included the difference in patient mortality at week four, were not met; however, Time to hospital discharge in patients treated with Actemra and placebo is 20 days and 28 days (median), respectively. COVACTA study did not identify any new safety signals for Actemra. Further analysis of the study results is needed to fully understand the data. The results will be submitted for publication in a peer-reviewed journal.

'COVID-19 is causing an unprecedented global crisis. it's the primary endpoint was not achieved, however, we believe that this study has provided useful data on the efficacy and safety of Actemra's inhibition of IL-6 signaling in patients with severe COVID-19 associated pneumonia. We will analyze the data in detail to obtain new insights for future development programs.' said Chugai's President and COO, Dr. Osamu Okuda.

The COVACTA study evaluated the safety and efficacy of intravenous Actemra added to standard-of-care treatment compared to treatment with placebo plus standard of care. The primary endpoint of clinical status in hospitalized adult patients with severe COVID-19 associated pneumonia was measured by a 7-category ordinal scale, which tracked patients' clinical status based on the need for intensive care and/or ventilator use, as well as supplemental oxygen requirements. The COVACTA study is the first global randomized, double-blind, placebo-controlled phase III study to investigate Actemra in adult patients hospitalized with severe COVID-19 associated pneumonia, with study locations in the US, Canada and Europe.

About the COVACTA study

COVACTA is a global, randomized, double-blind, placebo-controlled phase III study (COVACTA, NCT04320615) evaluating the safety and efficacy of intravenous Actemra added to standard of care in adult patients hospitalized with severe COVID-19 associated pneumonia compared to placebo plus standard of care. The primary and secondary endpoints include clinical status, mortality, mechanical ventilation and intensive care unit (ICU) variables at week four. Patients will be followed for 60 days post randomization.

About Actemra

Actemra is the first therapeutic antibody created in Japan by Chugai, and designed to block the activity of IL-6, a type of inflammatory cytokine. First launched in June, 2005, the drug intravenous injection is approved for six indications in Japan: Castleman's disease, rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, cytokine release syndrome induced by tumor-specific T cell infusion therapy, and adult Still's disease. In addition Actemra subcutaneous injection is approved for three indications in Japan: rheumatoid arthritis, Takayasu arteritis, giant cell arteritis. Actemra has obtained regulatory approval in more than 110 countries worldwide.

Contact:

Tel: +81-(0)3-3273-0554

Fax: +81-(0)3-3281-6607

(C) 2020 Electronic News Publishing, source ENP Newswire